INCB-086550
- Generic Name
- INCB-086550
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 7
- Registration Number
- NCT05101369
- Locations
- π¬π§
Covance Leeds Cru, Leeds, United Kingdom
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Incyte Biosciences Japan GK
- Target Recruit Count
- 3
- Registration Number
- NCT04674748
- Locations
- π―π΅
National Cancer Center Hospital - East, Chiba, Japan
π―π΅National Cancer Center Hospital, Tokyo, Japan
Study of INCB086550 in Select Solid Tumors
Phase 2
Terminated
- Conditions
- Non Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaMelanomaUrothelial Cancer
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT04629339
- Locations
- πΊπ¦
Medical Clinic Innovacia Llc, Vyshhorod, Ukraine
π§π¬Shatod Dr. Marko - Varna Ltd, Varna, Bulgaria
ππΊSemmelweis Egyetem, Budapest, Hungary
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 138
- Registration Number
- NCT03762447
- Locations
- π«π·
Icm Montpellier, Montpellier Cedex 5, France
π«π·Institut Universitaire Du Cancer de Toulouse Oncopole, Toulouse, France
πΊπΈJefferson University Hospitals, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath